FDA approves Carbaglu

FDA approved an NDA from Recordati S.p.A. (Milan:REC) for Carbaglu carglumic acid to treat hyperammonemia due to hepatic enzyme N-acetylglutamate synthetase (NAGS) deficiency, an inherited disorder th...